Orforglipron
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Orforglipron
- Molecular weight
- 882.97
- Structure (SMILES)
- Cc1cc(-n2nc3c(c2-n2ccn(-c4ccc5c(cnn5C)c4F)c2=O)[C@H](C)N(C(=O)c2cc4cc([C@H]5CCOC(C)(C)C5)ccc4n2[C@@]2(c4noc(=O)[nH]4)C[C@@H]2C)CC3)cc(C)c1F
- ly 3502970
- LY-3502970
- ly3502970
- Ly3502970
- LY3502970
- orforglipron
- Orforglipron
- orforglipron [INN]
- ORFORGLIPRON [USAN]
- Orforglipron [WHO-DD]
- orforglipron inn
- orforglipron usan
- orforglipron who dd
- CAS registry numbers
- 2212020-52-3
- ChEMBL ID
- CHEMBL4446782
- InChIKey
- USUWIEBBBWHKNI-KHIFEHGGSA-N
- PubChem compound IDs
- 137319706
- RxNorm IDs (RxCUI)
- 2739838
- FDA ingredient codes (UNII)
- 7ZW40D021M
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- orforglipron
- Type
- Synthetic organic
- Drug name stem
- -glipron
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 8.49
- Affinity units
- pKi
- Condition
- Obesity
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Hyperglycemia
- Highest recorded phase
- 1
- Condition identifier
- HP:0003074
- Subject identifier
- D006943
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004265
- Highest recorded phase
- 3
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0000822
- Highest recorded phase
- 3
- Condition identifier
- HP_0001399
- Highest recorded phase
- 1
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0003074
- Condition identifier
- HP_0010992
- Highest recorded phase
- 3
- Condition identifier
- HP_0025502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005386
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005416
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 3
- NCT04426474
- NCT05048719
- NCT05086445
- NCT05971940
- NCT06010004
- NCT06045221
- NCT06109311
- NCT06192108
- NCT05051579
- NCT05313802
- NCT05841238
- NCT06023095
- NCT06186622
- Hydrogen bond acceptors
- 13
- Hydrogen bond donors
- 1
- Polar surface area
- 155.93
- Calculated partition coefficient (ALogP)
- 7.44
- Calculated partition coefficient (XLogP)
- 6.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 7
- Heavy atoms
- 65
- Molecular formula
- C48H48F2N10O5
- Monoisotopic mass
- 882.37772099
- Natural product
- No
- Recorded assays
- 7
- Active assays
- 4
Active assay types
- Confirmatory
- Glucagon-Like Peptide-1 Receptor Agonists
Related records
Trials (52)
- A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
- A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
- A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
- A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
- A Multiple Dose Study of LY3502970 in Healthy Participants
- A Multiple-Dose Study of LY3502970 in Healthy Participants
- A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
- A Phase I Study of LY3502970 in Healthy Participants
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
- A Study of LY3502970 in Healthy Male Participants
In development for (6)
- Hyperglycemia Phase 1
- Hypertensive disorder Phase 3
- Obesity disorder Phase 2
- Osteoarthritis Phase 3
- Peripheral arterial disease Phase 3
- Type 2 diabetes mellitus Phase 3